MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

Rhea-AI Summary

MaxCyte has signed a clinical and commercial license agreement with Sana Biotechnology, granting Sana the rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive licensing fees and milestone payments. Doug Doerfler, MaxCyte's CEO, expressed enthusiasm for supporting Sana's cell therapy programs, highlighting the potential of Sana's hypoimmune cell platform. This collaboration aims to enhance the development of innovative cell-based treatments, reinforcing MaxCyte's position in the biopharmaceutical sector.

Positive

• Sana Biotechnology gains access to advanced Flow Electroporation® technology, potentially enhancing their cell therapy capabilities.
• MaxCyte will receive licensing fees and milestone payments, providing additional revenue streams.

Negative

• None.

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

Doug Doerfler, President and CEO of MaxCyte, said: "We are delighted to support Sana's ex vivo cell therapy programs and recognize the potential of the company's novel hypoimmune cell platform to advance treatments for serious diseases. This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments." 

MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies — including 20 of the top 25 pharmaceutical companies based on 2020 global revenue — to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer	+1 301-944-1660
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
Joint Corporate Broker Numis Securities Limited James Black / Duncan Monteith / Matthew  O'Dowd	+44 (0)20 7260 1000
Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams	+44 (0)20 7710 7600
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com
US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400   ir@maxcyte.com
US Media Relations Jamie Lacey-Moreira PressComm PR, LLC	+1 410-299-3310 jamielacey@presscommpr.com

View original content:https://www.prnewswire.com/news-releases/maxcyte-signs-clinical-and-commercial-license-with-sana-biotechnology-301350765.html

SOURCE Maxcyte, Inc.

FAQ

What agreement did MaxCyte sign with Sana Biotechnology?

MaxCyte signed a clinical and commercial license agreement with Sana Biotechnology for the use of its Flow Electroporation® technology.

What are the financial implications of the MaxCyte and Sana Biotechnology agreement?

MaxCyte is entitled to receive platform licensing fees and program-related milestone payments from Sana Biotechnology.

How does the agreement impact Sana Biotechnology's operations?

The agreement allows Sana Biotechnology to utilize advanced technology to enhance its cell therapy programs.

What technology is involved in the MaxCyte and Sana Biotechnology agreement?

The agreement involves MaxCyte's Flow Electroporation® technology and ExPERT™ platform.

What is the significance of the agreement for MaxCyte?

The agreement represents a key milestone in MaxCyte's strategy to expand its technology platform and support innovative treatments.